Details of the Drug Combination

General Information of Drug Combination (ID: DCXZ4PK)

Drug Combination Name
Indazole derivative 5 Pentostatin
Indication
Disease Entry Status REF
Carcinoma Investigative [1]
Component Drugs Indazole derivative 5   DMM1I8R Pentostatin   DM0HXDS
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: RXF 393
Zero Interaction Potency (ZIP) Score: 0.38
Bliss Independence Score: 3.99
Loewe Additivity Score: 4.54
LHighest Single Agent (HSA) Score: 4.73

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [4]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of Pentostatin
Disease Entry ICD 11 Status REF
Acute graft versus host disease 4B24.0 Approved [2]
Hairy cell leukaemia 2A82.2 Approved [3]
Leukemia N.A. Approved [2]
Pentostatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adenosine deaminase (ADA) TTLP57V ADA_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCLU4B4 MOLT-4 Investigative [6]
Anaplastic large cell lymphoma DCPBH2O SR Investigative [6]
Plasma cell myeloma DCEP3B2 RPMI-8226 Investigative [6]
Renal cell carcinoma DCLXGVN UO-31 Investigative [6]
Invasive ductal carcinoma DC0PW11 BT-549 Investigative [1]
Adenocarcinoma DC2E25E DU-145 Investigative [7]
Lung adenocarcinoma DCEENUE HOP-62 Investigative [7]
Lung adenocarcinoma DCTUXBK MDA-MB-231 Investigative [7]
Melanoma DCIGVM2 UACC-257 Investigative [7]
Melanoma DCQILY4 SK-MEL-2 Investigative [7]
Minimally invasive lung adenocarcinoma DCQ3ZUH NCI-H322M Investigative [7]
Ovarian serous cystadenocarcinoma DCL2UOU SK-OV-3 Investigative [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Pentostatin FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4805).
4 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
5 Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
6 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
7 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.